DB:0N6

Stock Analysis Report

Executive Summary

NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany.


Snowflake Analysis

Slightly overvalued with limited growth.

Share Price & News

How has NOXXON Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 0N6's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-13.2%

0N6

-2.3%

DE Biotechs

-0.2%

DE Market


1 Year Return

-37.6%

0N6

8.4%

DE Biotechs

13.7%

DE Market

Return vs Industry: 0N6 underperformed the German Biotechs industry which returned 8.4% over the past year.

Return vs Market: 0N6 underperformed the German Market which returned 13.7% over the past year.


Shareholder returns

0N6IndustryMarket
7 Day-13.2%-2.3%-0.2%
30 Day-13.2%-3.2%0.3%
90 Day37.5%6.3%3.7%
1 Year-37.6%-37.6%8.6%8.4%17.2%13.7%
3 Yearn/a44.5%42.9%15.4%5.3%
5 Yearn/a13.0%10.6%21.3%4.7%

Price Volatility Vs. Market

How volatile is NOXXON Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is NOXXON Pharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 0N6 (€0.5) is trading below our estimate of fair value (€9.18)

Significantly Below Fair Value: 0N6 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 0N6 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 0N6 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 0N6's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 0N6 has negative assets, so we can't compare its PB Ratio to the DE Biotechs industry average.


Next Steps

Future Growth

How is NOXXON Pharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

55.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0N6 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 0N6 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 0N6 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 0N6's revenue (49.9% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: 0N6's revenue (49.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 0N6's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has NOXXON Pharma performed over the past 5 years?

19.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 0N6 is currently unprofitable.

Growing Profit Margin: 0N6 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 0N6 is unprofitable, but has reduced losses over the past 5 years at a rate of 19.2% per year.

Accelerating Growth: Unable to compare 0N6's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0N6 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 0N6's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is NOXXON Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: 0N6 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: 0N6 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: 0N6 has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: 0N6's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: 0N6 has a low level of unsold assets or inventory.

Debt Coverage by Assets: 0N6 has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 0N6 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 0N6 has less than a year of cash runway if free cash flow continues to grow at historical rates of 35.1% each year.


Next Steps

Dividend

What is NOXXON Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.7%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 0N6's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 0N6's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 0N6's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 0N6's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 0N6's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.1yrs

Average board tenure


CEO

Aram Mangasarian (49yo)

4.6yrs

Tenure

€560,678

Compensation

Dr. Aram Mangasarian has been the Chief Executive Officer and Member of Executive Board at NOXXON Pharma AG since July 1, 2015 and served as its has been Chief Business Officer since May 18, 2010 and serve ...


CEO Compensation Analysis

Compensation vs Market: Aram's total compensation ($USD605.09K) is above average for companies of similar size in the German market ($USD412.50K).

Compensation vs Earnings: Aram's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Maurizio PetitBon
Chairman of the Supervisory Board0.8yrsno datano data
J. deBethizy
Member of Supervisory Board5.2yrs€145.90kno data
Bertram Köhler
Member of the Supervisory Board4.1yrsno datano data
Jan Burger
Member of Nox-A12 Advisory Board0yrsno datano data
Kai Hübel
Member of Nox-A12 Advisory Board0yrsno datano data
Ibrahim Yakoub-Agha
Member of Nox-A12 Advisory Board0yrsno datano data
Martin Brown
Member of Nox-A12 Advisory Board0yrsno datano data
Wolfgang Wick
Member of Nox-A12 Advisory Board0yrsno datano data
Hans-Joachim Anders
Member of Nox-E36 Advisory Board0yrsno datano data
Hermann Haller
Member of Nox-E36 Advisory Board0yrsno datano data

4.1yrs

Average Tenure

69yo

Average Age

Experienced Board: 0N6's board of directors are considered experienced (4.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 87.4%.


Top Shareholders

Company Information

NOXXON Pharma N.V.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NOXXON Pharma N.V.
  • Ticker: 0N6
  • Exchange: DB
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €7.439m
  • Shares outstanding: 16.50m
  • Website: https://www.noxxon.com

Number of Employees


Location

  • NOXXON Pharma N.V.
  • Max-Dohrn-Strasse 8-10
  • Berlin
  • Berlin
  • 10589
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALNOXENXTPA (Euronext Paris)YesOrdinary SharesFREURSep 2016
0N6DB (Deutsche Boerse AG)YesOrdinary SharesDEEURSep 2016

Biography

NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company’s Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase IIa clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/20 23:30
End of Day Share Price2020/02/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.